Our pipeline consists of first-in-class monoclonal antibodies and antibody-drug conjugates designed to target the metabolic dependencies of cancer cells. Our current focus areas are head and neck squamous cell carcinoma and pediatric osteosarcoma.

mAb

Pipeline

FZ01

*HNSCC - Head and neck squamous cell carcinoma

FZ05-YGT 86

Program

Asset

Clinical

IND enabling

Discovery

Lead nomination

ADC

In-collaboration with a pharma partner

HNSCC

FZ07

OS

Indication

In-collaboration with MSK

*OS - Osteosarcoma

OS

FZ01

FZ01 monoclonal antibody (mAb) targets a secreted lysosomal enzyme present in the tumor microenvironment. The enzyme is a validated cancer target involved in lipid metabolism and essential for dormant cancer cell reactivation. FZ01 is the first-in-class biological metabolic inhibitor.

FZ01 is in development for clinical use as an adjuvant therapy in combination with standard-of-care chemotherapy or targeted therapy to extend time in remission.

Supporting in-vivo evidence:

  • FZ01 prevents tumor re-growth after chemotherapy.

  • FZ01 enhances the effect of cisplatin chemotherapy on tumor growth.

  • FZ01 is effective against both dividing and non-dividing cancer cells.

FZ05

FZ05 ADC is a receptor-specific antibody designed to deliver a metabolic payload in osteosarcoma cells.

Frezent aims to test whether receptor-mediated delivery of a lipid-metabolism inhibitor can exploit metabolic vulnerabilities in therapy-resistant osteosarcoma while improving tumor-selective payload exposure.

FZ07

FZ07 ADC is also a receptor-specific antibody coupled with a cytotoxic payload. The antibody binds to the receptor expressed on the surface of dormant cancer cells. The receptor undergoes endocytosis and delivers the ADC to the lysosome where the payload is released.

FREZENT is interested in delivering a payload that blocks lipid metabolism in the lysosome, bringing a unique biology and first-in-class ADC modality for cancer therapy.

Frezent’s approach is first of its kind, designed to disrupt the metabolism of residual disease to prevent the cancer from coming back.